Boardman HM, Hartley L, Eisinga A et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015; (3): CD002229.
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Risikoinformationen: BfArM informiert über neue Ergebnisse zur Hormontherapie mit Tibolon nach den Wechseljahren. 2005.
Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG), Österreichische Gesellschaft für Gynäkologie und Geburtshilfe (OEGGG), Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe (SGGG). Peri- und Postmenopause - Diagnostik und Interventionen (S3-Leitlinie). AWMF-Registernr.: 015-062. 2020.
Formoso G, Perrone E, Maltoni S et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev 2016; (10): CD008536.
Furness S, Roberts H, Marjoribanks J et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012; (8): CD000402.
Grant MD, Marbella A, Wang AT et al. Menopausal Symptoms: Comparative Effectiveness of Therapies. (AHRQ Comparative Effectiveness Reviews; No. 147). 2015.
Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016; (8): CD001500.
MacLennan AH, Broadbent JL, Lester S et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; (4): CD002978.
Marjoribanks J, Farquhar C, Roberts H et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017; (1): CD004143.
Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004; 291(13): 1610-1620.
Ockene JK, Barad DH, Cochrane BB et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005; 294(2): 183-193.
Robert Koch-Institut (RKI), Statistisches Bundesamt (Destatis). Hormontherapie bei (post-)menopausalen Frauen in Deutschland 2007. Studienergebnisse zu Nutzen, Risiken und Versorgungsrealität (Gesundheitsberichterstattung des Bundes). Berlin: RKI; 2008.
Whelan AM, Jurgens TM, Trinacty M. Defining bioidentical hormones for menopause-related symptoms. Pharm Pract (Granada) 2011; 9(1): 16-22.
Zhang GQ, Chen JL, Luo Y et al. Menopausal hormone therapy and women's health: An umbrella review. PLoS Medicine / Public Library of Science 2021; 18(8): e1003731.
IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.